- Home
- EXAS vs IVZ Comparison
EXAS vs IVZ Comparison
Compare EXAS & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- IVZ
- Stock Information
- Founded
- EXAS 1995
- IVZ 1935
- Country
- EXAS United States
- IVZ United States
- Employees
- EXAS N/A
- IVZ N/A
- Industry
- EXAS Medical Specialities
- IVZ Investment Managers
- Sector
- EXAS Health Care
- IVZ Finance
- Exchange
- EXAS Nasdaq
- IVZ Nasdaq
- Market Cap
- EXAS 11.0B
- IVZ 9.9B
- IPO Year
- EXAS N/A
- IVZ 1995
- Fundamental
- Price
- EXAS $64.82
- IVZ $22.92
- Analyst Decision
- EXAS Strong Buy
- IVZ Hold
- Analyst Count
- EXAS 21
- IVZ 16
- Target Price
- EXAS $69.24
- IVZ $21.67
- AVG Volume (30 Days)
- EXAS 2.0M
- IVZ 5.3M
- Earning Date
- EXAS 11-03-2025
- IVZ 10-28-2025
- Dividend Yield
- EXAS N/A
- IVZ 3.65%
- EPS Growth
- EXAS N/A
- IVZ N/A
- EPS
- EXAS N/A
- IVZ 0.93
- Revenue
- EXAS $2,939,949,000.00
- IVZ $6,153,100,000.00
- Revenue This Year
- EXAS $16.68
- IVZ N/A
- Revenue Next Year
- EXAS $12.12
- IVZ $10.02
- P/E Ratio
- EXAS N/A
- IVZ $24.75
- Revenue Growth
- EXAS 12.55
- IVZ 5.83
- 52 Week Low
- EXAS $38.81
- IVZ $11.60
- 52 Week High
- EXAS $72.83
- IVZ $24.54
- Technical
- Relative Strength Index (RSI)
- EXAS 81.05
- IVZ 50.84
- Support Level
- EXAS $63.05
- IVZ $22.53
- Resistance Level
- EXAS $62.31
- IVZ $23.10
- Average True Range (ATR)
- EXAS 1.57
- IVZ 0.83
- MACD
- EXAS 0.27
- IVZ -0.15
- Stochastic Oscillator
- EXAS 92.60
- IVZ 61.25
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of July 2025, the firm had $2.025 trillion in assets under management spread among its equity (60% of AUM), balanced (3%), fixed-income (21%), alternative investment (6%), and money market (10%) operations. Passive products account for 46% of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).